These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
737 related articles for article (PubMed ID: 31422371)
1. Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method. von Rosenstiel C; Wiestler B; Haller B; Schmidt-Graf F; Gempt J; Bettstetter M; Rihani L; Wu W; Meyer B; Schlegel J; Liesche-Starnecker F J Clin Pathol; 2020 Feb; 73(2):112-115. PubMed ID: 31422371 [TBL] [Abstract][Full Text] [Related]
2. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study. Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343 [TBL] [Abstract][Full Text] [Related]
3. Predictive value of MGMT promoter methylation on the survival of TMZ treated Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600 [TBL] [Abstract][Full Text] [Related]
5. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis. Zhao H; Wang S; Song C; Zha Y; Li L World J Surg Oncol; 2016 Oct; 14(1):261. PubMed ID: 27733166 [TBL] [Abstract][Full Text] [Related]
6. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients. Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189 [TBL] [Abstract][Full Text] [Related]
7. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716 [TBL] [Abstract][Full Text] [Related]
8. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344 [TBL] [Abstract][Full Text] [Related]
9. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952 [TBL] [Abstract][Full Text] [Related]
10. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102 [TBL] [Abstract][Full Text] [Related]
11. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas. Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161 [TBL] [Abstract][Full Text] [Related]
13. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W; Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102 [TBL] [Abstract][Full Text] [Related]
14. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280 [TBL] [Abstract][Full Text] [Related]
15. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
16. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas. Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848 [TBL] [Abstract][Full Text] [Related]
17. Telomerase reverse transcriptase promoter mutation- and O Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540 [TBL] [Abstract][Full Text] [Related]
18. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811 [TBL] [Abstract][Full Text] [Related]
19. Hegi ME; Genbrugge E; Gorlia T; Stupp R; Gilbert MR; Chinot OL; Nabors LB; Jones G; Van Criekinge W; Straub J; Weller M Clin Cancer Res; 2019 Mar; 25(6):1809-1816. PubMed ID: 30514777 [TBL] [Abstract][Full Text] [Related]
20. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay? Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H J Neurosurg; 2019 Mar; 130(3):780-788. PubMed ID: 29726772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]